Physician profile
Satya Singh
NPI 1841252657
$2,069.90
in general payments reported to CMS, 2019-2025
13 companies · $546 in 2025
The $546 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $237 · 2021: $175 · 2022: $227 · 2023: $263 · 2024: $403 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $494.70 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $378.15 | 2021-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $275.00 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.78 | 2019-2022 | |
| Madrigal Pharmaceuticals | $171.10 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $146.53 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $109.76 | 2023 | Terlivaz |
| Redhill Biopharma INC. | $62.06 | 2021-2022 | |
| Boston Scientific Corporation | $49.34 | 2019-2022 | |
| Genzyme Corporation | $42.31 | 2023-2024 | |
| Braintree Laboratories, INC. | $37.65 | 2024 | Suflave, Sutab |
| Evoke Pharma, INC. | $30.98 | 2021 | |
| Merck Sharp & Dohme LLC | $23.54 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satya Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.